Apart from the development of TK domain inhibitors, the extracellular region of the EGFR, which is known as the binding site for native ligands EGF [21] and the monoclonal antibodies panitumumab and cetuximab [161], may also be targeted in the development of NSCLC treatments. Here, TKT is linked to non-small cell lung carcinoma.